ALK and non-small cell lung carcinoma: When stratified, the median survival was 6.01 (95% CI: 2.75-NA) years for patients who had immunotherapy for their NSCLC and an ALK or EGFR mutation that required targeted therapy in the form of TKIs and mAbs.